Abstract：Objectives To explore the therapeutic effect of Insulin Glargine combined with Acarbose on patients with overweight type 2 diabetes mellitus (T2DM).Methods A total of 42 patients with overweight T2DM admitted to our hospital from August 2016 to August 2019 were selected as the research objects.The selected patients were divided into the control group (21 cases) and the observation group (21 cases) according to random number table method.The control group was treated with Acarbose + Medium-acting Insulin,and the observation group was treated with Acarbose+ Insulin Glargine.After 2 months of continuous treatment,the total treatment efficiency,changes in glucose metabolism-related indexes,islet cell function,and hypoglycemia in the two groups were observed. Results After treatment,the total effective rate in the observation group (95.24%) was higher than that in the control group (71.42%),the difference was statistically significant (P<0.05).The fasting blood glucose (FBG),2 h postprandial blood glucose (2 h BG) and glycated hemoglobin (HbA1c) of the observation group were lower than those of the control group,the differences were statistically significant (P<0.05).The insulin secretion index (HOMA-β) in the observation group was higher than that in the control group,and the insulin resistance index (HOMA-IR) was lower than that in the control group,the differences were statistically significant (P<0.05).The incidence of hypoglycemia in the observation group (4.76%)was lower than that in the control group (28.57%),the difference was statistically significant (P<0.05).Conclusion For overweight T2DM patients,the clinical effect of Insulin Glargine combined with Acarbose is significant,which can effectively control blood sugar,improve islet cell secretion function,reduce hypoglycemia.
京公网安备 11010502046607号